Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

SWTX | SpringWorks Therapeutics Inc

IndexRUT P/E- EPS (ttm)-4.98 Insider Own22.95% Shs Outstand62.42M Perf Week-2.20%
Market Cap1.45B Forward P/E- EPS next Y-4.44 Insider Trans-0.03% Shs Float48.21M Perf Month-18.01%
Income-297.91M PEG- EPS next Q-1.33 Inst Own93.72% Short Float / Ratio30.24% / 28.07 Perf Quarter-8.62%
Sales0.00M P/S- EPS this Y-0.07% Inst Trans14.66% Short Interest14.58M Perf Half Y-6.05%
Book/sh7.22 P/B3.20 EPS next Y14.84% ROA-67.46% Target Price58.67 Perf Year-14.47%
Cash/sh7.62 P/C3.03 EPS next 5Y- ROE-76.67% 52W Range21.04 - 34.16 Perf YTD-11.11%
Dividend- P/FCF- EPS past 5Y-117.36% ROI-65.01% 52W High-32.32% Beta0.64
Dividend %- Quick Ratio11.55 Sales past 5Y-20.00% Gross Margin- 52W Low9.89% ATR1.31
Employees227 Current Ratio11.55 Sales Q/Q- Oper. Margin0.00% RSI (14)35.83 Volatility5.10% 4.74%
OptionableYes Debt/Eq0.02 EPS Q/Q11.34% Profit Margin- Rel Volume1.04 Prev Close24.17
ShortableYes LT Debt/Eq0.02 EarningsAug 02 BMO Payout- Avg Volume519.42K Price23.12
Recom1.14 SMA20-8.29% SMA50-14.29% SMA200-15.44% Volume540,791 Change-4.34%
Date Action Analyst Rating Change Price Target Change
Dec-01-22Initiated BofA Securities Buy $45
Jan-19-21Reiterated H.C. Wainwright Buy $87 → $101
Oct-29-20Reiterated H.C. Wainwright Buy $58 → $73
May-05-20Initiated Barclays Overweight $48
Mar-19-20Upgrade H.C. Wainwright Neutral → Buy $40 → $60
Mar-04-20Downgrade H.C. Wainwright Buy → Neutral $40
Jan-21-20Reiterated H.C. Wainwright Buy $34 → $40
Dec-04-19Initiated H.C. Wainwright Buy
Oct-08-19Initiated Wedbush Outperform $33
Oct-08-19Initiated JP Morgan Overweight $32
Oct-08-19Initiated Cowen Outperform
Sep-11-23 06:30AM
Aug-02-23 06:30AM
Jun-28-23 08:29PM
Jun-07-23 07:00AM
Jun-05-23 06:30AM
06:30AM Loading…
May-30-23 06:30AM
May-25-23 05:05PM
May-24-23 07:00AM
May-11-23 12:14PM
May-03-23 06:30AM
May-02-23 07:00AM
Apr-17-23 02:32PM
Mar-08-23 05:05PM
Mar-01-23 07:00AM
06:30AM Loading…
Feb-28-23 06:30AM
Feb-27-23 06:30AM
Jan-09-23 06:30AM
Jan-03-23 07:00AM
Dec-27-22 06:30AM
Nov-22-22 07:00AM
Nov-03-22 06:30AM
Nov-01-22 11:07AM
Sep-29-22 06:30AM
Sep-10-22 10:30AM
Sep-07-22 09:56AM
Aug-19-22 06:30AM
Aug-04-22 06:30AM
Aug-02-22 07:00AM
06:30AM Loading…
Jul-15-22 06:30AM
Jul-06-22 11:38AM
Jun-13-22 09:04AM
Jun-10-22 06:30AM
Jun-09-22 07:00AM
May-27-22 09:57AM
May-26-22 05:15PM
May-25-22 12:05PM
May-24-22 08:29AM
May-23-22 11:24AM
May-16-22 08:30AM
May-05-22 06:30AM
Apr-19-22 06:30AM
Mar-18-22 09:15AM
Feb-24-22 06:30AM
Feb-15-22 05:03PM
Feb-08-22 01:38PM
Feb-01-22 06:30AM
Jan-12-22 01:21PM
Jan-04-22 06:30AM
Dec-27-21 09:38PM
Dec-17-21 05:38PM
Dec-15-21 08:53AM
Dec-13-21 02:24PM
Dec-10-21 09:24AM
Dec-06-21 06:30AM
Nov-29-21 06:30AM
Nov-23-21 06:30AM
Nov-10-21 09:35AM
Nov-04-21 06:30AM
Oct-27-21 06:30AM
Oct-20-21 06:45AM
Sep-29-21 08:47AM
Sep-07-21 12:16PM
Aug-30-21 06:30AM
Aug-13-21 10:24AM
Aug-04-21 06:30AM
Aug-03-21 09:00AM
Jul-27-21 08:00AM
Jul-20-21 07:30AM
Jul-19-21 12:08PM
Jun-29-21 08:46AM
Jun-28-21 07:00AM
Jun-19-21 07:00AM
Jun-16-21 06:40AM
Jun-15-21 04:05PM
Jun-10-21 09:04AM
Jun-08-21 07:08AM
Jun-07-21 06:30AM
Jun-01-21 06:30AM
May-14-21 06:30AM
May-10-21 06:30AM
May-06-21 06:30AM
Apr-12-21 08:30AM
Apr-05-21 08:18AM
Apr-01-21 09:17AM
Mar-28-21 12:44PM
Mar-22-21 06:30AM
Mar-12-21 06:07PM
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, BGB-3245 (RAF Fusion and Dimer Inhibitor), SW-682 (TEAD Inhibitor), and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hambleton JulieDirectorJul 19Sale29.312,41870,8764,648Jul 21 04:13 PM
Hambleton JulieDirectorJun 20Sale26.922,40064,6037,066Jun 22 04:06 PM
Schwartz Jeffrey LawrenceDirectorMar 16Sale28.501,750,00049,875,0003,081,307Mar 20 05:00 PM
Hambleton JulieDirectorMar 15Sale31.501,10634,8414,818Mar 16 04:31 PM
Pichl DanielChief People OfficerJan 26Sale31.0085826,59835,203Jan 27 04:30 PM